EPI-7386

EPI-7386 is a nonsteroidal antiandrogen (NSAA) that is under investigation for the treatment of prostate cancer. It is being developed by ESSA Pharma and is currently in the phase I clinical trial stage. EPI-7386 works by binding to the androgen receptor (AR), preventing it from activating and promoting the growth of prostate cancer cells.

Mechanism of Action

EPI-7386 is a type of NSAA, which means it works by blocking the effects of androgens, such as testosterone. It does this by binding to the AR, which is found in many tissues throughout the body, including the prostate. When EPI-7386 binds to the AR, it prevents androgens from binding to the same receptor. This stops the AR from activating and promoting the growth of prostate cancer cells.

Development and Clinical Trials

EPI-7386 is being developed by ESSA Pharma, a pharmaceutical company that specializes in the development of treatments for prostate cancer. The drug is currently in the phase I clinical trial stage, which means it is being tested in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.

Potential Applications

If successful in clinical trials, EPI-7386 could be used to treat prostate cancer, particularly in cases where the cancer has become resistant to other forms of treatment. This could include cases of castration-resistant prostate cancer (CRPC), a form of the disease that continues to grow and spread even when the amount of testosterone in the body is reduced to very low levels.

See Also

• Nonsteroidal antiandrogen
• Androgen receptor
• Prostate cancer
• ESSA Pharma
• Castration-resistant prostate cancer

This article is a stub related to pharmacology. You can help WikiMD by expanding it!

   This article is a oncology stub. You can help WikiMD by expanding it!